Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05997693 · ClinicalTrials.gov registry record · Phase 3
One-Month DAPT in CABG Patients
A Phase 3 study of Chronic Coronary Disease, sponsored by Weill Medical College of Cornell University.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 700
- Enrollment target
- 20
- Study locations
NCT05997693: Recruiting Phase 3 study of Chronic Coronary Disease, sponsored by Weill Medical College of Cornell University.
NCT05997693 is a Phase 3 study of Chronic Coronary Disease that is actively recruiting participants, run by Weill Medical College of Cornell University. The registered enrollment target is 700 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05997693, a Phase 3 study of Chronic Coronary Disease, is actively recruiting participants, sponsored by Weill Medical College of Cornell University.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 700 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the effect of ticagrelor plus low-dose aspirin versus low-dose aspirin alone in patients with chronic coronary disease undergoing coronary artery bypass grafting.
Primary Outcome
This is a composite endpoint to be compared between groups in a hierarchical order using the win ratio method. The following hierarchy is pre-specified: 1. Time to all-cause mortality 2. Time to stroke 3. Time to myocardial infarction 4. Time to coronary revascularization 5. Presence of graft failure at 12-month imaging follow-up or on unscheduled imaging prior to 12 month
Conditions Studied
Interventions
- DRUG Low-dose aspirin
- DRUG Ticagrelor 90 MG
Study Locations (20)
Other
- Medical University Graz - Graz
- Johannes Kepler University Linz - Linz
- Medical University of Vienna - Vienna
- Beijing Anzhen Hospital - Beijing
- Center China Fuwai Hospital - Beijing
- University Hospital of Düsseldorf - Düsseldorf
- Westdeutsches Herz- und Gefäßzentrum Essen, Universität Duisburg-Essen - Essen
- Klinik für Herz- und Gefäßchirurgie - Universitäts-Herzzentrum Freiburg - Bad Krozingen - Freiburg im Breisgau
- University Hospital Giessen - Giessen
- Jena University Hospital - Jena
- LMU Klinikum Campus Großhadern - München
- Robert-Bosch-Krankenhaus Stuttgart - Stuttgart
- Sahlgrenska University Hospital - Gothenburg
New York
- NewYork-Presbyterian: Queens Hospital - Flushing
- Weill Cornell Medicine - New York
New Jersey
- Englewood Hospital - Englewood
Innsbruck
- Medical University Innsbruck - Innsbruck
Ontario
- University of Ottawa Heart Institute - Ottawa
China
- Ruijin Hospital: Shanghai Jiao Tong University School of Medicine - Shanghai
Jilian
- Jilin Heart Hospital - Changchun
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2024-08-15 |
| Est. Completion | 2031-01 |
| Phase | Phase 3 |
What NCT05997693 shows while recruiting
NCT05997693 is an interventional study that assigns participants to a tested intervention. The registered 700 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 1 condition, with Chronic Coronary Disease appearing as the primary indexed condition, and to 2 interventions - of which Low-dose aspirin is the first listed.
NCT05997693 names 20 study sites across 7 states, led by Other, New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT05997693 about?
NCT05997693 is a clinical study titled "One-Month DAPT in CABG Patients". The purpose of this study is to compare the effect of ticagrelor plus low-dose aspirin versus low-dose aspirin alone in patients with chronic coronary disease undergoing coronary artery bypass grafting.
What is the current status of trial NCT05997693?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 700 participants. The study started on 2024-08-15. Estimated completion is 2031-01.
What conditions does trial NCT05997693 study?
This clinical trial studies the following conditions: Chronic Coronary Disease.
What interventions are being tested in trial NCT05997693?
The interventions under investigation include: Low-dose aspirin (DRUG), Ticagrelor 90 MG (DRUG).
Who is sponsoring clinical trial NCT05997693?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05997693 being conducted?
This trial has 20 study locations across New Jersey, New York, Innsbruck, Ontario, China. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05997693's enrollment target sits among peer trials
700 506th of 2000 higher than 1,486 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900419 · 700 participants
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
- NCT01804686 · 700 participants · Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
- NCT02107989 · 700 participants
Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy and Establishment of a Normative Imaging Database
- NCT02129543 · 700 participants
Immune Reconstitution in Stem Cell Transplant Recipients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI